<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141253">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01929083</url>
  </required_header>
  <id_info>
    <org_study_id>12GRNT12060187</org_study_id>
    <nct_id>NCT01929083</nct_id>
  </id_info>
  <brief_title>Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening</brief_title>
  <official_title>Influence of Progesterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Female sex is an independent risk factor for the potentially fatal drug-induced  arrhythmia
      (irregular heartbeat) known as torsades de pointes (TdP), which is associated with
      prolongation of the corrected QT (QTc) interval on the electrocardiogram (ECG). Mechanisms
      for this increased risk in women are not well-understood. QTc interval duration has been
      shown to fluctuate throughout the phases of the menstrual cycle. Evidence indicates that the
      QTc interval response to drugs that may cause TdP is greater during the menses and ovulation
      phases of the menstrual cycle, during which serum progesterone concentrations are lowest,
      and lesser during the luteal phase, during which serum progesterone concentrations are
      highest. Additional evidence from our laboratory suggests that progesterone may be
      protective against TdP. Specific Aim 1: Establish the influence of oral progesterone
      administration as a preventive method by which to diminish the degree of drug-induced QT
      interval prolongation in women. Working hypothesis: Oral progesterone administration
      effectively attenuates enhanced drug-induced QT interval response in women. To test this
      hypothesis, progesterone or placebo will be administered in a crossover fashion to women
      during the menses phase of the menstrual cycle. QTc interval response to low-dose ibutilide,
      a drug known to lengthen the QT interval, will be assessed. The primary endpoint will be
      individually-corrected QT interval (QTcI) response to ibutilide, in the presence and absence
      of progesterone, which will be assessed by: 1) Effect on maximum change in QTcI, and 2) Area
      under the QTcI interval-time curves (AUEC). At the conclusion of this study, we will have
      established that oral progesterone administration is a safe and effective method of
      attenuating drug-induced QT interval prolongation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Maximum individual-corrected QT interval (QTcI)</measure>
    <time_frame>Following 7 days of progesterone or placebo administered in randomized, crossover fashion</time_frame>
    <safety_issue>No</safety_issue>
    <description>QT intervals will be corrected as follows: Prior to randomization, subjects will come to the Indiana Clinical Research Center for a 12-hour stay, during which three ECGs, one minute apart, will be obtained at the following times: 0, 15 &amp; 30 minutes, and 1, 2, 4, 6, 8, 12 and 24 hours. Subjects will be discharged, and then return then next morning for the 24 hour ECG. QT and RR intervals will be used to determine each subject's individual rate-corrected QT interval (QTcI) using the parabolic model QT = β•RRα, where RR is the interval between adjacent QRS complexes, and α and β are subject-specific correction factors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the QTcI - time curve (AUEC)</measure>
    <time_frame>Following 7 days of progesterone or placebo</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>QTcI EC50</measure>
    <time_frame>Following 7 days of progesterone or placebo</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum ibutilide concentration at 50% maximum QTcI lengthening</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of progesterone-associated adverse effects</measure>
    <time_frame>During 7 days of treatment with oral progesterone</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation between serum progesterone concentrations and each of the primary endpoints</measure>
    <time_frame>Following 7 days of progesterone or placebo</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Focus of the Study is to Determine if Oral Progesterone Administration Attenuates Drug-induced QT Interval Lengthening in Women</condition>
  <arm_group>
    <arm_group_label>Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive oral placebo, two capsules once daily every evening for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days</description>
    <arm_group_label>Progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive oral placebo two capsules once daily every evening for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Age 21-40 years

          -  Premenopausal

        Exclusion Criteria:

        Serum potassium ,&lt; 3.6 meq/l

          -  Serum magnesium  &lt; 1.8 mg/dl

          -  Serum hemoglobin &lt; 9.0 mg/dl

          -  Serum hematocrit &lt; 26%

          -  Hypertension

          -  Coronary artery disease

          -  Heart failure

          -  Liver disease

          -  Kidney disease

          -  Serum creatinine &gt; 1.5 mg/dl

          -  Taking hormone contraceptives

          -  Baseline Bazett's correct QTc interval &gt; 450 ms

          -  Family history of long-QT syndrome, arrhythmias, sudden cardiac death

          -  Concomitant use of any QT prolonging drug

          -  Pregnancy

          -  weight &lt; 45 kg

          -  Unwillingness to use non-hormonal forms of birth control during the study period
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>James E Tisdale, BSC, PharmD</last_name>
    <phone>317-613-2315</phone>
    <phone_ext>306</phone_ext>
    <email>jtisdale@purdue.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heather A Jaynes, MSN</last_name>
    <phone>317-613-2315</phone>
    <phone_ext>317</phone_ext>
    <email>hwroblew@iupui.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana Clinical Research Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Denne, MD</last_name>
      <phone>317-274-4920</phone>
      <email>sdenne@iupui.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sharon Cromer</last_name>
      <phone>317-278-3446</phone>
      <email>scromer2@iupui.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James E Tisdale, BSC, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heather Jaynes, MSN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard J Kovacs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin M Sowinski, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Flockhart, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Purdue University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James E Tisdale, BSc, PharmD</last_name>
      <phone>317-613-2315</phone>
      <phone_ext>306</phone_ext>
      <email>jtisdale@purdue.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather Jaynes, MSN</last_name>
      <phone>317-613-2315</phone>
      <phone_ext>317</phone_ext>
      <email>hwroblew@iupui.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James E Tisdale, BSc, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Overholser, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heather Jaynes, MSN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard J Kovacs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin M Sowinski, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Flockhart, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 26, 2013</lastchanged_date>
  <firstreceived_date>August 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Purdue University</investigator_affiliation>
    <investigator_full_name>James E. Tisdale</investigator_full_name>
    <investigator_title>Professor of Pharmacy Practice</investigator_title>
  </responsible_party>
  <keyword>Torsades de pointes</keyword>
  <keyword>Progesterone</keyword>
  <keyword>Clinical trial</keyword>
  <keyword>Risk reduction</keyword>
  <keyword>Electrocardiography</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Torsades de Pointes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
